Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations

Blood

Volumn 116, Issue 7, 2010, Pages 1114-1123

  Yang, Ying ^a   Létard, Sébastien ^a   Borge, Laurence ^a   Chaix, Amandine ^a   Hanssens, Katia ^a   Lopez, Sophie ^a   Vita, Marina ^a   Finetti, Pascal ^b   Birnbaum, Daniel ^b   Bertucci, François ^b   Gomez, Sophie ^a   De Sepulveda, Paulo ^a   Dubreuil, Patrice ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOTRANSFERASE; PROTEIN KINASE B; STEM CELL FACTOR RECEPTOR;

ADULT; ANIMAL; APOPTOSIS; CELL CULTURE; CHILD; COMPARATIVE STUDY; CYTOLOGY; ERYTHROLEUKEMIA; FIBROBLAST; FLOW CYTOMETRY; GENETICS; HUMAN; LYMPHOCYTE; MAST CELL; MASTOCYTOSIS; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; CHILD; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LYMPHOCYTES; MAST CELLS; MASTOCYTOSIS; MICE; MUTATION; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77956497048     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-226027     Document Type: Article

References (49)

1. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46(1):35-48.
2. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. J Invest Dermatol. 1991;96(3 suppl):15S-18S.
3. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419-432.
4. Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41(6):e88.
5. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis: in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30(4):373-378. (Pubitemid 43254957)
6. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560-10564.
7. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96(4):1609-1614. (Pubitemid 29098499)
8. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113(2):357-364. (Pubitemid 32523138)
9. Yarden Y, Kuang WJ, Yang FT, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6(11):3341-3351.
10. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008;180(8):5466-5476.
11. Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202(12):1635-1641. (Pubitemid 41815869)
12. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736.
13. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 2007;87(4):365-371. (Pubitemid 46474567)
14. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005;129(3):1042-1046. (Pubitemid 41242694)
15. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222-3225. (Pubitemid 38451702)
16. Yanagihori H, Oyama N, Nakamura K, Kaneko F. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn. 2005;7(2):252-257. (Pubitemid 40668308)
17. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-815.
18. Gari M, Goodeve A, Wilson G, et al. c-kit protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105(4):894-900. (Pubitemid 29309094)
19. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol. 2003;34(12):1306-1312. (Pubitemid 38018145)
20. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22(30):4710-4722. (Pubitemid 36976446)
21. Chian R, Young S, Danilkovitch-Miagkova A, et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. 2001;98(5):1365-1373.
22. Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 1995;85(3):790-798.
23. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6(7):1137-1145.
24. Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem. 2004;279(13):12249-12259. (Pubitemid 38445790)
25. Hashimoto K, Tsujimura T, Moriyama Y, et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol. 1996;148(1):189-200. (Pubitemid 26022450)
26. Tsai S, Bartelmez S, Sitnicka E, Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev. 1994;8(23):2831-2841. (Pubitemid 24374668)
27. Ning ZQ, Li J, McGuinness M, Arceci RJ. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene. 2001;20(33):4528-4536.
28. Shivakrupa R, Bernstein A, Watring N, Linnekin D. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 2003;63(15):4412-4419. (Pubitemid 36951012)
29. Sundstrom M, Vliagoftis H, Karlberg P, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003;108(1):89-97. (Pubitemid 36110869)
30. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. (Pubitemid 37328931)
31. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439-444.
32. Pedersen M, Ronnstrand L, Sun J. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell Signal. 2009;21(3):413-418.
33. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
34. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J. 2005;385(2):399-408.
35. Moriyama Y, Tsujimura T, Hashimoto K, et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J Biol Chem. 1996;271(7):3347-3350. (Pubitemid 26065636)
36. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007;130(2):323-334. (Pubitemid 47081138)
37. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-710. (Pubitemid 36159485)
38. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002;21(21):3314-3333. (Pubitemid 34587706)
39. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004;28(10):1319-1325. (Pubitemid 39336370)
40. Morley GM, Uden M, Gullick WJ, Dibb NJ. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene. 1999;18(20):3076-3084. (Pubitemid 29261228)
41. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265-273. (Pubitemid 40967202)
42. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-4349.
43. Shelburne CP, McCoy ME, Piekorz R, et al. Stat5 expression is critical for mast cell development and survival. Blood. 2003;102(4):1290-1297.
44. Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood. 2008;112(6):2463-2473.
45. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19(3):454-465.
46. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood. 2003;101(9):3436-3443. (Pubitemid 36857926)
47. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB. Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Exp Hematol. 2002;30(9):990-1000. (Pubitemid 35286615)
48. Gabillot-Carre M, Lepelletier Y, Humbert M, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood. 2006;108(3):1065-1072.
49. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood. 2007;110(7):2593-2599. (Pubitemid 47523183)